Home › Linfoma di Burkitt › Massachusetts
Studi clinici su Linfoma di Burkitt nello stato di Massachusetts
10 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Massachusetts.
Città nello stato di Massachusetts
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Dana-Farber Cancer Institute, Boston
In reclutamentoFase 3
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
In reclutamentoFase 1/2
6 Months – 25 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06395103Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT03666000Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- e altri 1
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 nov 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Dana Farber Cancer Institute, Boston
In reclutamentoFase 1/2
Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Floating Hospital for Children at Tufts Medical Center, Boston
- Dana Faber Cancer Institute/ Boston Children's Hospital, Boston
In reclutamentoFase 2
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 mag 2025 · NCT03509961Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.